Skip to content

Fast Assessment of STenosis Severity- FASTII Study

Multicenter Validation of 3D-QCA Based FFR vs. Pressure Wire Based FFR: The FAST-II Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03791320
Acronym
FASTII
Enrollment
330
Registered
2019-01-02
Start date
2018-10-15
Completion date
2019-11-01
Last updated
2020-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Fractional Flow Reserve, Coronary Physiology, 3D-QCA, Percutaneous coronary intervention

Brief summary

The Multicenter FAST (Fast Assessment of STenosis severity) study is a prospective observational multicenter study designed to evaluate the diagnostic accuracy of offline 3D-QCA based FFR, using CAAS Workstation (Pie Medical Imaging, Maastricht, the Netherlands) in identifying hemodynamically significant coronary artery disease with pressure wire-based FFR (≤0.80) as the reference standard.

Detailed description

The Multicenter FAST study is a prospective observational multicenter international study in which offline computation of vFFR is compared to conventional invasive, wire based FFR measurements. Pressure wire based FFR will be performed in patients with at least one intermediate coronary lesion at the discretion of the operator (typically defined as a coronary artery lesion with a diameter stenosis of 30-70% by visual assessment). A total of 3 two-dimensional angiography images, will be recorded and exported to the CAAS workstation 8.0 (Pie Medical Imaging, Maastricht, the Netherlands): two orthogonal views to create a 3D reconstruction of the coronary arteries and one view to ascertain the position of the FFR pressure wire. vFFR will be calculated automatically, by using the invasively measured aortic root pressure. vFFR measurements will be performed online by the different centers. In addition, all angiographic imaging data will be sent to an independent core laboratory (Cardialysis, Rotterdam, The Netherlands) for offline analysis.

Interventions

FFR measurement based on coronary angiography

Sponsors

Tokyo Medical University
CollaboratorOTHER
Centro Cardiologico Monzino
CollaboratorOTHER
Columbia University
CollaboratorOTHER
University Hospital Carl Gustav Carus
CollaboratorOTHER
University Hospital, Lille
CollaboratorOTHER
Erasmus Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients ≥ 18 years * indication procedure: stable, unstable angina or non-ST elevation acute coronary syndrome * Diagnostic coronary angiography or PCI with an indication to perform re-PCI FFR assessment of at least one coronary artery lesion.

Exclusion criteria

* ST-elevation myocardial infarction (STEMI) * Cardiogenic shock * Severe hemodynamic instability * Adenosine intolerance * Lesions containing thrombus, left main lesions, grafts, arteries with collaterals

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic accuracy of vFFR to identify FFR (≤0.8 or >0.8) calculated by corelab1 yearThe diagnostic accuracy of offline vFFR assessed by a blinded independent core laboratory to identify hemodynamically-significant coronary stenosis with FFR (≤0.8 or \>0.8) as the reference standard.

Secondary

MeasureTime frameDescription
Diagnostic accuracy of vFFR to identify FFR (≤0.8 or >0.8) calculated by site/operator1 yearThe diagnostic accuracy of operator or cathlab technician calculated online vFFR to identify hemodynamically-significant coronary stenosis with FFR (≤0.8 or \>0.8) as the reference standard.
Interobserver variability1 year3D-QCA based FFR (vFFR) will be calculated twice: by the operator/technician of different centers AND by an independent corelab (Cardoalysis). Correlation and agreement between these two measurements will be assessed in order to investigate the Inter-observer variability.

Countries

France, Germany, Italy, Japan, Netherlands, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026